These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 29338455)

  • 1. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clear cell meningiomas: three case reports with genetic characterization and review of the literature.
    Ohba S; Sasaki H; Kimura T; Ikeda E; Kawase T
    Neurosurgery; 2010 Sep; 67(3):E870-1; discussion E871. PubMed ID: 20683214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
    Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
    J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.
    Pham MH; Zada G; Mosich GM; Chen TC; Giannotta SL; Wang K; Mack WJ
    Neurosurg Focus; 2011 May; 30(5):E7. PubMed ID: 21529178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New prospects for management and treatment of inoperable and recurrent skull base meningiomas.
    Johnson MD; Sade B; Milano MT; Lee JH; Toms SA
    J Neurooncol; 2008 Jan; 86(1):109-22. PubMed ID: 17624496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningioma.
    Marosi C; Hassler M; Roessler K; Reni M; Sant M; Mazza E; Vecht C
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):153-71. PubMed ID: 18342535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of radiotherapy in the management of high-grade meningiomas.
    Hwang KL; Hwang WL; Bussière MR; Shih HA
    Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S5. PubMed ID: 28758409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
    Birzu C; Peyre M; Sahm F
    Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meningiomas: new prognostic factors].
    Sanz Esponera J
    An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meningioma: management of the most common brain tumour].
    Hundsberger T; Surbeck W; Hader C; Putora PM; Conen K; Roelcke U
    Praxis (Bern 1994); 2016 Apr; 105(8):445-51. PubMed ID: 27078728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and Prognostic Predictors of Anaplastic Meningiomas.
    Masalha W; Heiland DH; Delev D; Fennell JT; Franco P; Scheiwe C; Mercas BI; Mader I; Schnell O; Grauvogel J
    World Neurosurg; 2019 Nov; 131():e321-e328. PubMed ID: 31356972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Atypical and Anaplastic Meningiomas.
    Buttrick S; Shah AH; Komotar RJ; Ivan ME
    Neurosurg Clin N Am; 2016 Apr; 27(2):239-47. PubMed ID: 27012388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology and clinical management challenges in meningioma.
    Mawrin C; Chung C; Preusser M
    Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningiomas: Overview and New Directions in Therapy.
    Wang N; Osswald M
    Semin Neurol; 2018 Feb; 38(1):112-120. PubMed ID: 29548058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade meningiomas: biology and implications.
    Bi WL; Prabhu VC; Dunn IF
    Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in the pathology of skull base tumors.
    Radner H; Katenkamp D; Reifenberger G; Deckert M; Pietsch T; Wiestler OD
    Virchows Arch; 2001 Apr; 438(4):321-35. PubMed ID: 11355165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
    Martinez NL; Khanna O; Farrell CJ
    Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria.
    Pearson BE; Markert JM; Fisher WS; Guthrie BL; Fiveash JB; Palmer CA; Riley K
    Neurosurg Focus; 2008; 24(5):E3. PubMed ID: 18447742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.